A carregar...
Mutant Isocitrate Dehydrogenase Inhibitors as Targeted Cancer Therapeutics
The identification of heterozygous neomorphic isocitrate dehydrogenase (IDH) mutations across multiple cancer types including both solid and hematologic malignancies has revolutionized our understanding of oncogenesis in these malignancies and the potential for targeted therapeutics using small mole...
Na minha lista:
| Publicado no: | Front Oncol |
|---|---|
| Main Authors: | , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Frontiers Media S.A.
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6534082/ https://ncbi.nlm.nih.gov/pubmed/31165048 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2019.00417 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|